Reach Us +44-1470-490003


Huang Wei Ling

CEO, infectious and parasitic diseases, Medical Acupuncture and Pain Management Clinic, Brazil, E-mail: [email protected]

Visit for more related articles at Journal of Autoimmune Disorders

Resistant interceded provocative maladies measure an appallingly fundamental plan of unending issue that influence 5–7% of western peoples. Regardless of the way that they're regularly novel to the extent their signs and key patient economics, they're pathophysiologically related; being depicted by deregulation of safe pathways relate ruined a graceless response. Overall, ailment adjusting against rheumatic pharmaceutical, to an incredible degree summed up grouping of general little molecule based masters, square measure used in the primary line treatment of those illnesses. This square measure supplemented in a couple of cases by shorterterm adrenal cortical steroid therapeutic care, another characterization of to an extraordinary degree summed up pros.


Notwithstanding, as these medications generally speaking disregard to summon relate degree attractive semi-ceaseless response, an outsized second-line therapeutic care fragment has ascended in these business divisions, starting with the support of Remicade (infliximab) and (etanercept) in 1998. This zone includes generally of premium general life shape Antibodies (mAbs), those square measure extraordinarily fiscally useful due to their expansive utilize and high regard. Notwithstanding the way that the licenses for a couple of those mAbs either have authoritatively invalid or square measure because of pass all through the check total, the market is foreseen to aptitude continuing with advancement.


Regardless of the way that the licenses for a couple of those mAbs either have viably invalid or are an immediate aftereffect of slip by all through the gauge whole, the market is foreseen to expertise continuing with advancement, from $61.5 billion out of 2015 to $74.2 billion out of 2022, at a compound yearly rate of two.71%.

The global Immunology Market is likely to expand in the coming years driven by the high prevalence of immunological disorders, resulting from environmental factors. According to a report published by Fortune Business Insights, titled “IMMUNOLOGY MARKET: GLOBAL MARKET ANALYSIS, INSIGHTS AND FORECAST, 2019-2026,” the market was valued at US$ 77,365.4 Mn in 2018. Fortune Business Insights has predicted that the market will reach US$ 143,833.2 Mn by 2026 and will exhibit a CAGR of 8.1%.

The global Immunology Market is likely to expand in the coming years driven by the high demand for immunology drugs resulting from the high prevalence of immunological disorders. The severity of immunological disorders has created an increasing awareness around the world. Various initiatives and advisory programs have been conducted by the government as well as public organizations. This, in turn, will fuel the demand for immunology drugs. Furthermore, the increased efficiency of immunology drugs has contributed to better patient outcomes, which in turn has led to subsequent growth of the global Immunology Market.

The spate of recent regulatory approvals for the immunology products is anticipated to contribute to the overall positive growth of the market. For instance, the recent regulatory approval and the subsequent launch of TREMFYA (Guselkumab) by Janssen Global Services, LLC (Johnson & Johnson), is expected to lead to better outcome for the patients. TREMFYA (Guselkumab) was launched for the treatment of moderate to severe plaque psoriasis, a seriously debilitating immunological disorder. TREMFYA is the only biologic approved for the treatment of moderate to severe plaque psoriasis, that selectively blocks the interleukin (IL)-23, leading to a vast improvement in the symptoms of the patient. Apart from being one of the emerging drugs of the Immunology Market, Fortune Business Insights predicts that Janssen Global Services, LLC (Johnson & Johnson) latest product offering will have a positive impact on the global Immunology Market in the forthcoming years.

The global Immunology Market has gained impetus from the availability of several regulatory approved drugs. The approval of new drugs and the trends of improvements in clinical efficiencies will bode well for the global Immunology Market. In 2019, AbbVie received approval from the Food and Drug Administration (FDA) for the usage of ‘SKYRIZI’. The drug was aimed at the treatment of moderate to severe plaque psoriasis. This drug was inclined towards the treatment of adults diagnosed with psoriasis and have been recommended for or undergoing therapy. The drug is likely to gain huge popularity among healthcare professionals and its high clinical efficacy will fuel the demand in the coming years

Besides product launches and drug approvals, Fortune Business Insights assesses several other factors that have made significant growth contributions to the global Immunology Market. Companies are encouraged by the growing usage approvals by regulatory authorities across the world. Several company mergers and acquisitions have also accounted for growth of the global Immunology Market.

The report also offers key insights related to an overview of the immunology market - for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, prevalence of autoimmune and immunological disorders by key countries, regulatory scenario by key regions, key industry developments, overview of regulatory scenario by key countries, an overview of current advances in R&D for immunology.

Size, Share and Global Trend by Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form (Liquid, Lyophilized), By End User (Hospitals, Clinics, Homecare) and Geography Forecast till 2026

Intravenous Immunoglobulin’s Market Size, Share and Global Trend by Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain- Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), Form (Liquid, Lyophilized), End User (Hospitals, Clinics, Homecare) & Geography Forecast till 2025

There are numerous factors driving and limiting the immunology drug market. Among the various diseases, Rheumatoid Arthritis therapeutics accounted to the largest market segment in immunology. Improved treatment options with TNF therapies drive this crowded market. There is a large pipeline of drugs to come out and the rise in clinical trials shows the growth in this area. Patent expirations will also cause the market to move forward as less expensive biosimilars makes their entry into the market. While there are many factors driving the market, strong barriers are keeping the overall value from increasing too heavily. These range from stringent FDA regulations, regulatory barriers on biosimilars, and the increase in pricing pressure due to competition.

The global immunology drugs report provides market analysis, sizing, forecasts, and market shares of the immunology drugs. The report analyses key factors instrumental in changing the market scenario and provide a forecast of the future immunology market globally. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.

The global markets as defined in the reports include the United States, Europe (EU5 – The United Kingdom, Spain, Italy, Germany, France and others), and Rest of World (Brazil, Russia, India, China, Japan, and Canada).

Select your language of interest to view the total content in your interested language

Viewing options

Recommended Conferences
Post your comment

Share This Article

Flyer image

Post your comment

captcha   Reload  Can't read the image? click here to refresh